Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The company in-licenses and develops drug candidates for commercial use and is devoted to delivering innovative products to patients with cancer. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California. The company's lead product candidate is Neratinib, an orally active, irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. The company has additional drug candidates in various stages of development.